The UK and US have signed a major bilateral deal that will maintain zero duties on British pharmaceutical products being sold in the US market.
Agreement Details of the Accord
In exchange for the tariff guarantee, the UK has committed to increase funding on medicines through the National Health Service (NHS). This commitment secures that tariffs on these key exports will be held at zero for a duration of 36 months.
This agreement is in response to recent statements to significantly raise tariffs on branded drug imports, with potential rates mentioned as high as double the cost.
"This arrangement with the Britain strengthens the international landscape for cutting-edge drugs and establishes long-overdue fairness to American-British drug exports," an announcement noted.
Trade Impact
Medicines constitute one of the UK's largest goods shipped to the America, which is by far the largest market for large UK drugmakers.
Export figures show that in the 12 months to the end of the third quarter, the UK shipped pharmaceutical products totaling over eleven billion pounds to the US. This figure accounted for a significant portion of all goods exports in that span.
"This agreement protects employment, stimulates funding and facilitates the UK to establish itself as a global hub for medical research," a government official stated.
Specific NHS Changes
The agreement includes several notable changes from the British government:
- Higher Cost Ceiling: The UK will raise the affordability limit at which it judges new medicines to be prohibitively costly by a quarter.
- Boosted Medicine Funding: There is a goal to increase overall NHS spending on medicines from 0.3 percent of Gross Domestic Product to 0.6% over the following ten-year period.
- Payback Limit: The percentage manufacturers must pay back to the NHS to stay within budget will be capped at 15%. Last year, rebates topped twenty percent.
Industry Background
The pact follows a ongoing row between the drug companies and the UK government over medicine costs and regulatory access.
The disagreement were intensified by claims that US patients were paying several times more for the equivalent treatments than people in the other developed nations.
In recent months, several significant manufacturing plans in the UK have been paused or scrapped, while multi-billion-dollar expansions have been directed toward projects in the United States.
The Science Minister stated that the NHS must increase expenditure on drugs, noting that its expenditure on drugs had shrunk as a percentage of its resources over the previous ten-year period.
